ライフサイエンスコーパス: papillary thyroid carcinoma

1 Of the 93 patients, 57 (61%) had papillary thyroid carcinoma.

2 by the active RET mutant, RET/PTC1, found in papillary thyroid carcinoma.

3 tic factor for the metastatic progression of papillary thyroid carcinoma.

4 BRAF gene mutation is frequently detected in papillary thyroid carcinoma.

5 osomal rearrangements found in radio-induced papillary thyroid carcinoma.

6 iration of the mass suggested a diagnosis of papillary thyroid carcinoma.

7 thrombosis is an extremely rare condition in papillary thyroid carcinoma.

8 stologic and cytologic similarities to human papillary thyroid carcinoma.

9 uced iodide uptake ability observed in human papillary thyroid carcinoma.

10 he peripheral blood of only one patient with papillary thyroid carcinoma.

11 his oncogene has been detected only in human papillary thyroid carcinomas.

12 ngements are one of the genetic hallmarks of papillary thyroid carcinomas.

13 of the RET tyrosine kinase commonly seen in papillary thyroid carcinomas.

14 re believed to be tumor-initiating events in papillary thyroid carcinomas.

15 of the RET proto-oncogene detected in human papillary thyroid carcinomas.

16 d three different somatic mutations (23%) in papillary thyroid carcinomas.

17 s, are frequently found in radiation-induced papillary thyroid carcinomas.

18 as been reported to be associated with human papillary thyroid carcinomas.

19 revalent in radiation-induced post-Chernobyl papillary thyroid carcinomas.

20 pothesis that RET/PTC is sufficient to cause papillary thyroid carcinomas.

21 is aberrant methylation is evident in 83% of papillary thyroid carcinoma, 11% of follicular thyroid c

22 Molecular profiles of 11 papillary thyroid carcinomas, 13 follicular variant of p

23 thyroid carcinomas, 13 follicular variant of papillary thyroid carcinomas, 9 follicular thyroid carci

24 of cutaneous melanomas, cutaneous nevi, and papillary thyroid carcinoma and in a small fraction of o

25 e length were found in follicular variant of papillary thyroid carcinomas and follicular adenomas.

26 ion protein which is frequently expressed in papillary thyroid carcinomas and has been detected in th

27 active protein, not only in FTCs but also in papillary thyroid carcinomas and Hurthle cell carcinomas

28 (55 FA, 27 follicular thyroid carcinomas, 35 papillary thyroid carcinomas, and 22 undifferentiated th

29 reviously been implicated in pathogenesis of papillary thyroid carcinoma as a fusion partner of RET.

30 st commonly detected BRAF mutations in human papillary thyroid carcinomas (BRAF(V600E)) in thyroid fo

31 ll lines and samples of human follicular and papillary thyroid carcinoma by reverse transcriptase-pol

32 region shared by FOXE1 and PTCSC2 in a human papillary thyroid carcinoma cell line (KTC-1) and unaffe

33 Furthermore, the papillary thyroid carcinoma cell line could be induced t

34 ay in primary thyroid follicular cells and a papillary thyroid carcinoma cell line in vitro.

35 ransforming growth factor-beta1 (TGF-beta1), papillary thyroid carcinoma cells acquired increased can

36 pecificity of 96.2% (3 follicular variant of papillary thyroid carcinomas clustered with the benign l

37 mphoma, chronic myelomonocytic leukaemia and papillary thyroid carcinoma described similar rearrangem

38 n, and that PRRX1 plays an important role in papillary thyroid carcinoma EMT and disease progression.

39 We demonstrated previously that papillary thyroid carcinomas exhibit aberrant patterns o

40 d tumor DNA from 17 pediatric post-Chernobyl papillary thyroid carcinomas for mutations at three diff

41 Like the other papillary thyroid carcinoma forms of Ret, Ret/ptc2 is ac

42 A patient with papillary thyroid carcinoma had stable disease for more

43 d a remarkable increase in radiation-induced papillary thyroid carcinoma in children and young adults

44 Papillary thyroid carcinomas in humans are associated wi

45 yroid carcinoma oncogene (RET/PTC) generates papillary thyroid carcinomas in one genetic step.

46 thyroidectomy caused by local recurrence of papillary thyroid carcinoma is extremely rare.

47 Papillary thyroid carcinoma is frequently multifocal.

48 d demonstrate that alternative exon usage in papillary thyroid carcinomas is restricted primarily to

49 patients thyroidectomized for follicular or papillary thyroid carcinoma may represent the thymus.

50 ovel strategies to prevent or to treat human papillary thyroid carcinomas, MEN 2 disease, as well as

51 MDS, and both solid tumors (osteosarcoma and papillary thyroid carcinoma) occurred in recipients of D

52 Current evidence suggests the papillary thyroid carcinoma oncogene (RET/PTC) generates

53 epithelial cells were microinjected with the papillary thyroid carcinoma oncogene (RET/PTC1 short iso

54 Papillary thyroid carcinoma overexpress transforming gro

55 A substantial increase in papillary thyroid carcinoma (PTC) among children exposed

56 ological examination of the mass confirmed a papillary thyroid carcinoma (PTC) and enlarged metastati

57 es of nonmedullary thyroid carcinoma, namely papillary thyroid carcinoma (PTC) and follicular thyroid

58 protein RET/PTC3 (RP3) that is expressed in papillary thyroid carcinoma (PTC) and thyroid epithelia

59 observed that 63 of 110 (57%) human primary papillary thyroid carcinoma (PTC) cases expressed nuclea

60 MTC and follicular tumours resembling human papillary thyroid carcinoma (PTC) depending on the found

61 Papillary thyroid carcinoma (PTC) displays higher herita

62 Papillary thyroid carcinoma (PTC) displays strong but so

63 Although papillary thyroid carcinoma (PTC) displays strong herita

64 Many patients undergoing thyroidectomy for papillary thyroid carcinoma (PTC) have subclinical nodal

65 Papillary thyroid carcinoma (PTC) is clinically heteroge

66 Papillary thyroid carcinoma (PTC) is the most common typ

67 Biomarkers of papillary thyroid carcinoma (PTC) metastasis can accurat

68 A genome-wide association study of papillary thyroid carcinoma (PTC) pinpointed two indepen

69 Papillary thyroid carcinoma (PTC) remained to be the mos

70 Approximately 40 percent of patients with papillary thyroid carcinoma (PTC) typically have either

71 600E) is the most common somatic mutation in papillary thyroid carcinoma (PTC), how it induces tumor

72 One such disease, papillary thyroid carcinoma (PTC), is the leading endocr

73 Papillary thyroid carcinoma (PTC), the most frequent thy

74 NP (rs965513) firmly associated with risk of papillary thyroid carcinoma (PTC).

75 rticularly those associated with a precursor papillary thyroid carcinoma (PTC).

76 earrangements, which are frequently found in papillary thyroid carcinoma (PTC).

77 young age at exposure and risk of developing papillary thyroid carcinoma (PTC).

78 tively little is known about the genetics of papillary thyroid carcinoma (PTC).

79 ral soluble factors that were induced by RET/papillary thyroid carcinoma (PTC)3 gene expression inclu

80 Genetic analysis of human papillary thyroid carcinomas (PTC) has revealed unique c

81 Most papillary thyroid carcinomas (PTC) have an isozyme-speci

82 sequencing and expression analysis of eight papillary thyroid carcinomas (PTC) to comprehensively ch

83 ted BRAF is detected in approximately 45% of papillary thyroid carcinomas (PTC).

84 he number of genetic alterations detected in papillary thyroid carcinomas (PTC).

85 ion is the most common genetic alteration in papillary thyroid carcinomas (PTC).

86 is the most prevalent genetic alteration in papillary thyroid carcinomas (PTC).

87 prognostication and treatment selection for papillary thyroid carcinomas (PTCs) do not uniformly pre

88 Papillary thyroid carcinomas (PTCs) that invade into loc

89 95 sporadic thyroid tumors, of which 39 were papillary thyroid carcinomas (PTCs), 12 were follicular

90 occurs in various thyroid neoplasms such as papillary thyroid carcinomas (PTCs), follicular thyroid

91 is the most common endocrine malignancy, and papillary thyroid carcinoma represents the most common t

92 tive activation of the RET proto-oncogene in papillary thyroid carcinomas results from rearrangements

93 embers of the rearranged during transfection/papillary thyroid carcinoma (RET/PTC) fusion oncogene fa

94 ing RET chimeric oncoproteins found in human papillary thyroid carcinomas (RET/PTC) as well as RET on

95 tergenic, noncoding RNA gene (lincRNA) named Papillary Thyroid Carcinoma Susceptibility Candidate 3 (

96 Papillary thyroid carcinomas that invade locally or meta

97 id-targeted expression of ret/PTC1 developed papillary thyroid carcinomas that were minimally invasiv

98 Combi-TA mice developed papillary thyroid carcinomas, the incidence of which was

99 s strongly correlated with the generation of papillary thyroid carcinomas, the most prevalent maligna

100 ssed cDNA fragments were isolated from human papillary thyroid carcinoma tissues, among them a cDNA w

101 To gain insight into the pathogenesis of papillary thyroid carcinoma, transcriptional profiles of

102 We conclude that papillary thyroid carcinoma tumor cells exhibit increase

103 None of the cases of papillary thyroid carcinoma was positive for ras oncogen

104 sidual neck thyroid tissues of patients with papillary thyroid carcinoma were quantified.

105 nscripts were associated with follicular and papillary thyroid carcinomas, whereas long telomeres and

106 We report a case of papillary thyroid carcinoma which invades IJV with hyper

107 HB/SDHD mutation carriers have renal cell or papillary thyroid carcinomas, which are also CS-related

108 mutations in p53 were found by SSCP in 2/33 papillary thyroid carcinomas, with one missense mutation